Edgewise Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Edgewise Therapeutics, Inc. (EWTX) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $9.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-06
- Edgewise Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $9.36M, a 21.07% increase year-over-year.
- Edgewise Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $8.71M, a 3.80% decline year-over-year.
- Edgewise Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $8.09M, a 17.51% increase year-over-year.
- Edgewise Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $7.73M, a 48.03% increase year-over-year.
- Edgewise Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $34.75M, a 40.63% increase from fiscal 2024.
- Edgewise Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $24.71M, a 40.72% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $17.56M, a 60.75% increase from fiscal 2022.
- Edgewise Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $10.92M, a 148.05% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.36M 10-Q · filed 2026-08-06 | $18.08M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $8.71M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $34.75M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $8.09M 10-Q · filed 2025-11-06 | $15.82M derived: sum of 2 quarters · filed 2026-08-06 | $24.88M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $7.73M 10-Q · filed 2026-08-06 | $16.79M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $9.06M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $24.71M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $6.88M 10-Q · filed 2025-11-06 | $12.10M derived: sum of 2 quarters · filed 2025-11-06 | $16.98M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $5.22M 10-Q · filed 2025-11-06 | $10.10M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $4.87M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $17.56M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $4.56M 10-Q · filed 2024-11-07 | $8.57M derived: sum of 2 quarters · filed 2024-11-07 | $12.41M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $4.01M 10-Q · filed 2024-11-07 | $7.85M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $3.84M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $10.92M 10-K · filed 2024-02-22 | |||
| 2022-09-30 | $3.17M 10-Q · filed 2023-11-09 | $5.21M derived: sum of 2 quarters · filed 2023-11-09 | $7.19M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $2.04M 10-Q · filed 2023-11-09 | $4.01M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $1.98M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $4.40M 10-K · filed 2023-02-23 | |||
| 2021-09-30 | $1.55M 10-Q · filed 2022-11-03 | $2.23M derived: sum of 2 quarters · filed 2022-11-03 | $2.53M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $687.00K 10-Q · filed 2022-11-03 | $983.00K derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $296.00K 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $354.00K 10-K · filed 2022-02-24 | |||
| 2020-09-30 | $70.00K 10-Q · filed 2021-11-10 | $119.00K derived: sum of 2 quarters · filed 2021-11-10 | $164.00K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $49.00K 10-Q · filed 2021-11-10 | $94.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $45.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |